Cwm LLC Has $111,000 Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

CWM LLC decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 96.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,197 shares of the company's stock after selling 55,009 shares during the period. CWM LLC's holdings in Ionis Pharmaceuticals were worth $111,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IONS. Tennessee Valley Asset Management Partners bought a new stake in shares of Ionis Pharmaceuticals in the 4th quarter worth about $34,000. Peoples Bank KS bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $39,000. China Universal Asset Management Co. Ltd. increased its stake in Ionis Pharmaceuticals by 95.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,670 shares of the company's stock worth $166,000 after purchasing an additional 1,795 shares during the period. Mitchell & Pahl Private Wealth LLC bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth $210,000. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Ionis Pharmaceuticals in the third quarter worth about $224,000. Hedge funds and other institutional investors own 93.86% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on IONS. JPMorgan Chase & Co. lifted their price objective on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a "neutral" rating in a report on Thursday, February 1st. William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, April 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. StockNews.com raised shares of Ionis Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, February 24th. Finally, Royal Bank of Canada upped their price target on shares of Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an "outperform" rating in a report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.67.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 6,000 shares of the firm's stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $42.71, for a total value of $256,260.00. Following the completion of the transaction, the director now owns 16,346 shares of the company's stock, valued at approximately $698,137.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 6,000 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $42.71, for a total transaction of $256,260.00. Following the completion of the transaction, the director now owns 16,346 shares in the company, valued at approximately $698,137.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Baroldi sold 4,006 shares of the company's stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the completion of the transaction, the executive vice president now directly owns 19,631 shares of the company's stock, valued at $816,649.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,393 shares of company stock valued at $440,127. Corporate insiders own 2.65% of the company's stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS traded down $1.35 during mid-day trading on Tuesday, reaching $40.93. The company's stock had a trading volume of 1,211,831 shares, compared to its average volume of 1,116,861. The company has a debt-to-equity ratio of 3.18, a quick ratio of 5.83 and a current ratio of 5.90. Ionis Pharmaceuticals, Inc. has a 1-year low of $34.79 and a 1-year high of $54.44. The stock has a 50-day moving average of $42.99 and a two-hundred day moving average of $46.96. The stock has a market capitalization of $5.97 billion, a P/E ratio of -15.99 and a beta of 0.41.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The business had revenue of $325.00 million during the quarter, compared to analysts' expectations of $176.01 million. During the same period in the prior year, the business posted ($0.37) EPS. The company's revenue was up 113.8% compared to the same quarter last year. On average, equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.76 EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.